Pressinformation 25 August, 2011

The order covers CoreTherm ® treatment system for the indication of benign prostatic hyperplasia (BPH). The order value is over two million SEK, with good opportunities to follow orders.

-The order is important and we hope it can open for more business in the distributor level in the future, “says Anders Elf, International Sales Manager at ProstaLund Operations AB.

ProstaLund ® is active in medical technology. The company develops and sells equipment for the treatment of benign prostatic hyperplasia based on a patented, individually-tailored microwave. The treatment, which takes about 13 minutes, is done under local anesthesia with the treatment results are in line with procedures requiring several days of hospitalization. More than 20 000 men have undergone treatment with CoreTherm ® and method now used at over 200 hospitals and clinics in Sweden, Europe and USA.

“We have now a positive momentum in the market and it’s great to be able to welcome more new employees in the process of developing CoreTherm a first choice for treatment of benign prostatic hyperplasia, an inconvenience that one in two men aged over 50 will be checked out during its life “said Ulf Rosén CEO, ProstaLund

ProstaLund ® is active in medical technology. The company develops and sells equipment for the treatment of benign prostatic hyperplasia based on a patented personalized heat treatment. The treatment, which takes about 13 minutes, is done under local anesthesia with the treatment results are in line with procedures requiring several days of hospitalization. More than 20 000 men have undergone treatment with CoreTherm ® and method now used at over 200 hospitals and clinics in Sweden, Europe and USA.

The primary cause of men seeking medical help is anxiety about their prostate problems. Unfortunately, the doctor does not always share their concern. Despite the availability of several different treatment methods to cure prostate problems, about 50 percent of the respondents’ doctors consider that it is something “related to age – wait and see”, and leave the patient and his ailment without treatment. This also leaves patients with a nagging worry that their problem could nonetheless be prostate cancer – which it does not need to be.

Poorer quality of life

40 percent of the respondents get up between two and five times each night. BPH (Benign Prostatic Hyperplasia) also affects the partner negatively in the form of disturbed sleep and diminished sex life. As many as 46 percent say that their sleep is disrupted sometimes or the whole time. Half also think that their sex life is affected negatively by prostate problems. More men consider today that their quality of life is poorer in conjunction with their prostate troubles. In a survey performed in 2004, about 20 percent of men experienced an impaired quality of life. Today, the figure is 34 percent who feel that their quality of life has deteriorated. For example, they avoid playing sports, travelling or going out to a restaurant.

Improved reception

The survey also showed the aspects that patients miss in their contact with the doctor: effective treatment, more information about different treatments – advantages and disadvantages, taking problems sincerely, and being received well and taken seriously.

Waiting times

The Swedish Association of Local Authorities and Regions (SKL) has a website (vantetider.se) that indicates the length of waiting times for treatment within urology. Most clinics in Sweden currently have at least 13 weeks’ waiting time. ./.

For further information, please contact:

Ann Baron, Marketing Manager, +46 (0)70-744 44 80.
ann.baron@prostalund.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it

ProstaLund has developed a new appliance for the treatment of prostate glands with a smaller degree of enlargement. The new appliance is designed to be used when the enlarged prostate has a weight of 20 to 50 grams. Prostate weight is normally estimated to be about 20 grams – although depending on how the gland has grown, minor enlargement can also create the same troublesome symptoms as a significantly more enlarged prostate.

The new appliance is based on the Company’s well-established and documented CoreTherm treatment system and is composed of a new treatment catheter, microwave antenna and temperature probes that are all adapted to operate effectively on smaller prostate glands.

The new appliance is CE-labelled and approved for sale within the EU.

“We believe that the potential underlying volume of patients where CoreTherm is a suitable treatment option is increasing by about 10-15 percent. We perceive it as a further strength to now be able to offer our clients a treatment option that embraces a broader spectrum – thus enabling us to standardize the treatment of BPH to CoreTherm. Our objective is now to have the new appliance approved in other countries where CoreTherm has already been approved by requisite authorities and is used clinically,” says Ulf Rosén, CEO of ProstaLund.

He continues by saying: “The United States is a prioritized market and our application for approval of the short appliance has also been submitted to the CDRH/FDA. We are now awaiting their independent evaluation of our documentation.”

For further information, please contact:

Ulf Rosén, President & CEO, +46 (0)706-86 29 16.
ulf.rosen@prostalund.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it
ProstaLund® operates within the medical technology sector. The Company develops and markets equipment for the treatment of benign prostate enlargement based on patented individually adapted microwave treatment. The procedure is carried out with local anaesthetic with results comparable to those of surgery requiring several days’ hospitalization. Over 20,000 men have undergone treatment with CoreTherm® and the method is currently used at more than 200 hospitals and surgical centres in the United States and Europe. www.prostalund.com

“We are now entering a new phase through Ann Baron joining the organization in Sweden. An International Sales & Marketing Manager, with many years’ experience of sales and market communication within the sector, will enable us to both develop and strengthen our position on the market. Ann Baron will be a key person in our new drive,” says Ulf Rosén, President & CEO of ProstaLund.

“I will focus on a greater physical presence with our current and potential customers. Another important role I will take on is to develop and improve ProstaLund’s presence on the Internet and other digital media, as well as contacts with the press. The treatment is relatively easy and mild for the patient, provides documented good results and is cost-effective to use. It is my task to ensure that as many people as possible are aware of this,” says Ann Baron.

CoreTherm is currently installed at about 20 clinics and private healthcare providers in Sweden, where approximately 6,500 men have undergone treatment. In total, more than 20,000 patients have been treated with CoreTherm.

./.

For further information, please contact:

Ulf Rosén, President & CEO, +46 (0)706-86 29 16.
Ulf.rosen@prostalund.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it

ProstaLund® operates within the medical technology sector. The Company develops and markets equipment for the treatment of benign prostate enlargement based on patented individually adapted microwave treatment. The procedure, which takes about 13 minutes, is carried out with local anaesthetic with results comparable to those of surgery requiring several days in hospital. Over 20,000 men have undergone treatment with CoreTherm® and the method is currently used at more than 200 hospitals and medical centres in Sweden, the rest of Europe and the United States.

www.prostalund.com